Killing capacity analysis of tumor-infiltrating cytotoxic lymphocytes and impact on lymph node metastasis in differentiated papillary carcinoma of thyroid with the BRAF V600E mutation

Table 2 Relativity indexes of the differential killing capacity of NK cells and CTLs in tumor tissues and paracancerous tissues with or without CCLNM in PTC

	Group B(n = 17)	Group A(n = 27)	t	P
CD3⁺P⁺(%)_T	8.21 ± 1.32	9.42 ± 1.59	-0.552	0.584
CD3⁺P⁺(%)_N	9.71 ± 1.6	14.52 ± 2.64	-1.56	0.127
t	-1.068	-2.245
p	0.3	0.034*
CD3⁺G⁺(%)_T	19.66 ± 3.26	21.59 ± 2.63	-0.465	0.644
CD3⁺G⁺(%)_N	15.76 ± 2.75	24.25 ± 4.09	-1.565	0.125
t	1.842	-0.799
p	0.083	0.432
CD8⁺P⁺(%)_T	7.87 ± 1.43	9.37 ± 1.4	-0.725	0.472
CD8⁺P⁺(%)_N	9.56 ± 1.62	8.84 ± 1.43	0.326	0.746
t	-0.877	0.297
p	0.393	0.769
CD8⁺G⁺(%)_T	25.71 ± 3.56	30.2 ± 2.98	-0.969	0.338
CD8⁺G⁺(%)_N	18 ± 2.16	21.75 ± 2.26	-1.147	0.258
t	1.963	3.264
p	0.066	0.003*
CD16-CD56 + P+(%)_T	29.56 ± 4.38	29.2 ± 4.01	0.058	0.954
CD16-CD56 + P+(%)_N	37.49 ± 6.13	33.49 ± 4.59	0.532	0.598
t	-1.761	-0.985
p	0.096	0.334
CD16-CD56 + G+(%)_T	29.58 ± 4.23	31.76 ± 3.82	-0.378	0.708
CD16-CD56 + G+(%)_N	36.16 ± 6.13	31.98 ± 4.44	0.565	0.575
t	-1.895	-0.067
p	0.075	0.947

Values are expressed as the mean ± standard error of the mean (SEM). Within-group comparisons
were made using paired t tests, and comparisons between groups were made using independent
samples t test, *represents significant differences (P < 0.05)

ISSN: 1746-1596